Document:

exv10w3

 

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked
“[Intentionally Redacted]” and has been filed separately with the Securities and Exchange
Commission pursuant to a Confidential Treatment Application filed with the Commission.

EXHIBIT 10.3

FIRST AMENDMENT TO LICENCE AGREEMENT

DATED AUGUST 28, 2001 BETWEEN

JOHNSON MATTHEY PLC

AND

NEOTHERAPEUTICS, INC.

This First Amendment to License Agreement (“FIRST AMENDMENT”) is entered into and effective this
30th day of September 2002 by and between Johnson Matthey PLC, a company organised under the laws
of England and Wales whose registered office is at 2-4 Cockspur Street, Trafalgar Square, London,
SW1Y 5BQ, England, acting for itself and for its AFFILIATES including particularly Johnson Matthey,
Inc (collectively, “LICENSOR”), and NeoTherapeutics, Inc., a corporation organized under the laws
of the State of California, United States of America whose principal place of business is at 157
Technology Drive, Irvine, California 92618, United States of America with reference to the
following facts and on the following terms and conditions.

RECITALS

(A) Effective August 28, 2001, LICENSOR and LICENSEE entered into the License Agreement (the
“LICENSE”) pursuant to which LICENSOR granted a license for the use of technical information
relating to the use of platinum complex JM216 in the treatment of tumor cells as well as for the
use of the PATENT RIGHTS (as defined in the LICENSE). All defined terms in this FIRST AMENDMENT (as
set forth in capital letters) shall have the same meaning as set forth in the LICENSE.

(B) The parties now wish to amend and modify the LICENSE on the terms and conditions as set forth
in this FIRST AMENDMENT.

Now therefore, for good and valuable consideration, the parties agree as follows:

1

 

(1) ARTICLE I

Paragraph 16 of Article I of the LICENSE shall be amended to read as follows:

TERM: the term commencing on the EFFECTIVE DATE and terminating on a country-by-country basis upon
the expiry of the last to expire of the patents granted in each such country which have expiration
dates specified on Schedule A. The date of expiration of a patent described in this Section shall
include any extension granted to LICENSOR by virtue of any continuation, continuations-in-part and
divisional applications, including reissues and reexamination applications and patents and
reexamination certificates, patent term extensions, Supplemental Protection Certificates or like
term extensions issuing to LICENSOR in any country.

(2) ARTICLE II

Paragraph 1 of Article II of the LICENSE shall be amended to read as follows:

1. Subject to Article II.3 below, the LICENSOR agrees to grant and hereby grants to the LICENSEE an
exclusive worldwide royalty-bearing revocable right and licence, with rights to sublicence, under
the PATENT RIGHTS to use PLATINUM COMPLEXES, the LICENSOR’S INFORMATION and the LICENSOR’S ONGOING
INFORMATION to make, have made, use, offer to sell, and have sold PRODUCTS for use within the
FIELD.

Paragraph 2 of Article II of the LICENSE shall be amended to read as follows:

2. The LICENSEE shall be entitled to sub-license any THIRD PARTY under rights granted under Article
II.1 hereof provided that the LICENSEE shall remain responsible for all acts and omissions of such
sub-licensee as though they were by the LICENSEE. In particular, the LICENSEE shall be responsible
to the LICENSOR for payments due in respect of sales by sub-licensees as though they were sales by
LICENSEE. The terms of any sub-license agreement shall provide that upon termination of this
Agreement, any

2

 

sub-licensee shall attorn to and accept the LICENSOR in place of the LICENSEE such that any
sub-license shall be deemed an agreement between the LICENSOR and sub-licensee.

(3) ARTICLE III

Paragraph 1 of Article III of the LICENSE shall be amended to read as follows:

1. The LICENSEE, its AFFILIATES and sub-licensees shall diligently perform research and development
on the use of JM 216 and other PLATINUM COMPLEXES within the FIELD and on the formulation of
PRODUCTS. The LICENSEE, its AFFILIATE and sub-licensees shall exercise in the performance of such
research technical skill and competence of a high calibre.

(4) ARTICLE IV

Article IV of the LICENSE shall be amended to read as follows:

1. The LICENSEE, its AFFILIATES and sub-licensees shall use its best efforts to test, evaluate and
develop PRODUCTS so as to meet the objectives detailed hereunder:

Objective

1 Submission of NDA to US FDA (hereinafter called the ‘First MILESTONE’)

2 Acceptance of NDA by US FDA (hereinafter called the ‘Second MILESTONE’)

3 Receipt of US FDA approval of NDA (hereinafter called the ‘Third MILESTONE’)

4 Approval in the first European Union state of a new drug application (hereinafter called the ‘Fourth MILESTONE’)

3

 

5 Approval by US FDA of JM216 for the first indication other than the indication approved in
Objective 2. (hereinafter called the ‘Fifth MILESTONE’)

6 Approval in the first European Union state of JM216 for the first indication other than the
indication approved in Objective 3.

(hereinafter called the `Sixth MILESTONE’)

(5) ARTICLE V

Paragraphs 1 through 5, inclusive of Article V of the LICENSE shall be amended to read as follows:

1. The LICENSOR acknowledges receipt of US$100,000 which was paid by LICENSOR on the EFFECTIVE
DATE;

2. The LICENSOR acknowledges receipt of US$150,000 as required by Article V.2 of the LICENSE.

3. Within 30 (thirty) days of the date of the attainment of each MILESTONE by the LICENSEE, an
AFFILIATE or sub-licensee, the LICENSEE shall pay to the LICENSOR the following sums:

	 	 	 
	(i) the First MILESTONE:

	 	Issuance of shares of LICENSEE’s restricted
	 

	 	common stock in accordance with Section 9 of this
	 

	 	First Amendment
	 
	(ii) the Second MILESTONE

	 	US$500,000
	 
	(iii) the Third MILESTONE:
	 	[Intentionally Redacted]

	 
	(iv) the Fourth MILESTONE:
	 	[Intentionally Redacted]

	 
	(v) the Fifth MILESTONE:
	 	[Intentionally Redacted]

	 
	(vi) the Sixth MILESTONE:

	 	[Intentionally Redacted]

In no event will LICENSEE be liable for more than one payment upon the occurrence of each
MILESTONE.

4

 

4. The LICENSEE shall during the TERM of this Agreement pay to the LICENSOR a royalty calculated at
the rate set forth below of the NET SALES VALUE of all PRODUCTS sold or otherwise supplied for use
whether within the FIELD or outside the FIELD for money or money’s worth by LICENSEE or any
AFFILIATE or sublicensee thereof; provided, however, that in any country in the TERRITORY where a
GENERIC PRODUCT is sold in competition with the PRODUCT, the royalty payable to LICENSOR with
respect to NET SALES of such PRODUCTS in such country shall be reduced to 0%, commencing with the
calendar quarter during which any such GENERIC PRODUCT first becomes available in competition with
the PRODUCT in such country.

Royalty Rate NET SALES during calendar year

[Intentionally Redacted]

5. Payments due under Article V.4 shall be made within 45 days of the end of each calendar quarter
in respect of royalties accruing on PRODUCTS invoiced in that calendar quarter. Paragraphs 7 and 8
of Article V of the LICENSE shall be amended to read as follows:

7. The LICENSEE agrees during for a period of three (3) years following the accrual of any royalty
it will keep and maintain accurate records and books of account containing all data necessary for
determination of royalties payable under this Agreement, including records and books of account
relating to sales of PRODUCTS by sub-licensees, which records and books of account of LICENSEE
shall upon reasonable notice by LICENSOR be open at all reasonable times during reasonable business
hours for inspection by an independent accountant appointed by LICENSOR for the purpose of
verifying the accuracy of the LICENSEE’s reports hereunder. Such accountant shall be entitled to
take copies solely of LICENSEE’s records pertaining to such reports as LICENSOR’s

5

 

expense. The LICENSEE shall ensure that its sub-licensees (if any) also keep true and accurate
records and books of account containing all data necessary for the determination of royalties
payable in respect of their activities and shall ensure that such records and books of account
shall upon reasonable notice by the LICENSOR be open for inspection at all reasonable times during
business hours for inspection by such independent accountant no less than once per year for
purposes of verifying the accuracy of the LICENSEE’S reports hereunder.

8. The LICENSEE shall submit to the LICENSOR within 45 days of the end of each calendar quarter a
statement setting forth with respect to the operations of the LICENSEE hereunder, as well as with
regard to each sub-licensee during that period, the quantity of PRODUCTS made and sold and the NET
SALES VALUE of all PRODUCTS sold together with payments due.

(6) ARTICLE VII

Paragraph 6 of Article VII of the LICENSE shall be amended by inserting the following after the
first sentence:

LICENSOR further represents and warrants that it is not aware of any patents, whether granted to
LICENSOR, an AFFILIATE, or any THIRD PARTY, which would be infringed by: (i) the making, using and
selling of any PRODUCT; (ii) or utilization of any PLATINUM COMPLEX by LICENSEE in accordance with
the license granted by this AGREEMENT; or (iii) the metabolites of JM216. To the best of LICENSOR’s
knowledge and belief, the practice of the PATENT RIGHTS and the exercise of the rights granted
LICENSEE under Article II.1 do not infringe upon or conflict with any patent, copyright or other
proprietary right of any THIRD PARTY.

6

 

(7) ARTICLE IX

The first sentence of Paragraph 1 of Article IX of the LICENSE shall be amended by to read as
follows:

1. During the continuance of this Agreement the LICENSEE, its AFFILIATES, and its sub-licensees
shall:

(8) ARTICLE XI.

Paragraph 3 of Article XI shall be amended to read as follows

3. Intentionally deleted.

Subparagraph 8.3 of Article XI shall be amended to read as follows:

8.3 Upon any termination of this Agreement, sublicenses granted by the LICENSEE shall be
automatically assigned to the LICENSOR which shall thereafter receive all benefits and have all
obligations under the sublicenses as in place and stead of the LICENSEE.

(9) ISSUANCE OF LICENSEE SHARES TO LICENSOR; INVESTMENT REPRESENTATIONS; VOTING TRUST; PIGGYBACK
REGISTRATION RIGHTS

[Intentionally Redacted]

(10) GENERAL PROVISIONS

(a) This FIRST AMENDMENT may be executed in two or more counterparts, including facsimile
signatures, each of which will be deemed an original, but all of which together will constitute one
and the same instrument.

(b) This FIRST AMENDMENT and the AGREEMENT constitute the complete and integrated agreement of the
parties with respect to the subject matter hereof and

7

 

thereof. Except as provided in this FIRST AMENDMENT, the AGREEMENT will remain in full force and
effect and unchanged in all other respects.

(c) LICENSOR represents that it is not aware of any default by LICENSEE under the Agreement.

The parties have caused this FIRST AMENDMENT to be executed by their respective authorized
representatives effective as of the date first set forth above.

	 	 	 	 	 	 	 
	 

	 	LICENSOR
	 	LICENSEE
	 	 
	 

	 	Johnson Matthey PLC
	 	NeoTherapeutics, Inc.	 	 
	 
	 	 	 	 	 	 
	 

	 	By: /s/ Ian Wishart
	 	By: /s/ Rajesh Shrotriya	 	 
	 

	 	 
	 	 	 	 
	 

	 	Its: Group Patents and
	 	Its: Chairman, CEO and	 	 
	 

	 	Licensing Controller
	 	                President	 	 
	 

	 	 
	 	 	 	 

8exv10w4

 

Pursuant to 17 CTR 240.24b-2, confidential information has been omitted in places marked “[***]"

and has been filed separately with the Securities and Exchange Commission pursuant to a

Confidential Treatment Application filed with the Commission.

EXHIBIT 10.4

LICENSE AGREEMENT

by and between

INDENA SPA

and

SPECTRUM PHARMACEUTICALS, INC.

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 
	 	Page
	1. DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	1.1 Affiliate
	 	 	1	 
	1.2 cGMP
	 	 	2	 
	1.3 Confidential Information
	 	 	2	 
	1.4 Controlled
	 	 	2	 
	1.5 DMF
	 	 	2	 
	1.6 EMEA
	 	 	3	 
	1.7 Event of Default
	 	 	3	 
	1.8 FDA
	 	 	3	 
	1.9 First Commercial Sale
	 	 	3	 
	1.10 GAAP
	 	 	3	 
	1.11 IDN 5109
	 	 	3	 
	1.12 Improvements
	 	 	3	 
	1.13 IND
	 	 	3	 
	1.14 Joint Inventions
	 	 	3	 
	1.15 Joint Patent
	 	 	3	 
	1.16 Know-How
	 	 	3	 
	1.17 License
	 	 	4	 
	1.18 Licensed Compound or “API”
	 	 	4	 
	1.19 Licensed Field
	 	 	4	 
	1.20 MAA
	 	 	4	 
	1.21 MHLW
	 	 	4	 
	1.22 Milestone Payments
	 	 	4	 
	1.23 NDA
	 	 	4	 
	1.24 Net Sales
	 	 	4	 
	1.25 Patent
	 	 	5	 
	1.26 Patent Rights
	 	 	5	 
	1.27 Product
	 	 	5	 
	1.28 Regulatory Approval
	 	 	5	 
	1.29 Regulatory Authority
	 	 	5	 
	1.30 Regulatory Filings
	 	 	5	 
	1.31 Royalty Term
	 	 	5	 
	1.32 Technology
	 	 	6	 
	1.33 Term
	 	 	6	 
	1.34 Territory
	 	 	6	 
	1.35 Third Party
	 	 	6	 
	1.36 Valid Claim
	 	 	6	 
	 
	 	 	 	 
	2. LICENSE
	 	 	6	 
	 
	 	 	 	 
	2.1 License
	 	 	6	 
	2.2 Sublicenses
	 	 	6	 
	2.3 Technology and Material Transfer
	 	 	6	 
	2.4 Exceptions to Exclusivity
	 	 	6	 
	2.5 Regulatory Filings
	 	 	7	 
	 
	 	 	 	 
	3. FINANCIAL TERMS AND CONDITIONS
	 	 	7	 
	 
	 	 	 	 
	3.1 Upfront and Milestone Payments
	 	 	7	 
	3.2 Product Royalties
	 	 	9	 
	3.3 Payments
	 	 	10	 

i 

 

	 	 	 	 	 
	 
	 	Page
	3.4 Records
	 	 	10	 
	3.5 Income or Other Tax Withholding
	 	 	10	 
	3.6 Audit
	 	 	11	 
	3.7 Late Payments
	 	 	11	 
	 
	 	 	 	 
	4. OWNERSHIP AND PATENT MATTERS
	 	 	11	 
	 
	 	 	 	 
	4.1 Ownership
	 	 	11	 
	4.2 Prosecution and Maintenance of Patent Rights
	 	 	12	 
	4.3 Infringement Actions
	 	 	13	 
	 
	 	 	 	 
	5. OBLIGATIONS RELATED TO SUPPLY, DEVELOPMENT, MARKETING AND
COMMERCIALIZATION
	 	 	14	 
	 
	 	 	 	 
	5.1 Spectrum’s Diligence Obligations
	 	 	15	 
	5.2 Research and Development
	 	 	15	 
	5.3 Governmental Approvals
	 	 	15	 
	5.4 Supply of API
	 	 	15	 
	 
	 	 	 	 
	6. INDEMNITY
	 	 	16	 
	 
	 	 	 	 
	6.1 Spectrum Indemnification
	 	 	16	 
	6.2 Indena Indemnification
	 	 	16	 
	6.3 Indemnity Procedure
	 	 	17	 
	 
	 	 	 	 
	7. REPRESENTATIONS AND WARRANTIES
	 	 	18	 
	 
	 	 	 	 
	7.1 By Indena
	 	 	18	 
	7.2 By Spectrum
	 	 	20	 
	 
	 	 	 	 
	8. ADDITIONAL COVENANTS
	 	 	21	 
	 
	 	 	 	 
	8.1 Preservation of Title
	 	 	21	 
	8.2 No Conflicts
	 	 	21	 
	 
	 	 	 	 
	9. CONFIDENTIALITY AND PUBLICATION
	 	 	21	 
	 
	 	 	 	 
	9.1 Treatment of Confidential Information
	 	 	21	 
	9.2 Public Statements
	 	 	22	 
	 
	 	 	 	 
	10. TERM, DEFAULT AND TERMINATION
	 	 	23	 
	 
	 	 	 	 
	10.1 Term of Agreement
	 	 	23	 
	10.2 Unilateral Termination — Spectrum
	 	 	23	 
	10.3 Default
	 	 	23	 
	10.4 Insolvency
	 	 	24	 
	10.5 Effects of Expiration or Termination
	 	 	24	 
	10.6 Work-in-Progress
	 	 	27	 
	 
	 	 	 	 
	11. DISPUTE RESOLUTION
	 	 	27	 
	 
	 	 	 	 
	11.1 Arbitration
	 	 	27	 
	11.2 Administration
	 	 	28	 
	11.3 Waivers
	 	 	28	 
	11.4 Non-Arbitrable Disputes
	 	 	28	 

ii 

 

	 	 	 	 	 
	12. GENERAL PROVISIONS
	 	 	28	 
	 
	 	 	 	 
	12.1 Further Assurances
	 	 	28	 
	12.2 Independent Contractors
	 	 	28	 
	12.3 Entire Agreement; Modification
	 	 	29	 
	12.4 Force Majeure
	 	 	29	 
	12.5 Limitation of Liability
	 	 	29	 
	12.6 Assignment
	 	 	29	 
	12.7 Governing Law
	 	 	29	 
	12.8 Headings
	 	 	29	 
	12.9 Interpretation
	 	 	29	 
	12.10 Severability
	 	 	30	 
	12.11 No Waiver
	 	 	30	 
	12.12 Notices
	 	 	30	 
	12.13 Compliance with Laws
	 	 	31	 
	12.14 Counterparts
	 	 	31	 

iii 

 

LICENSE AGREEMENT

     This License Agreement (this “Agreement”) is entered into as of July 17, 2007 (the
“Effective Date”), by and between SPECTRUM PHARMACEUTICALS, INC. (“Spectrum”), a Delaware
corporation having offices at 157 Technology Drive, Irvine, CA 92618 and INDENA SPA (“Indena”), an
Italian company having offices at Viale Ortles 12, 20139 Milano, Italy. Indena and Spectrum may
each be referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

     A. WHEREAS, Indena owns the rights to a compound known as IDN 5109 used in treating cancer in
humans and has acquired and developed certain know-how concerning such compound.

     B. WHEREAS, IDN 5109 is the subject of patents in the United States, the European Union and
Japan.

     C. WHEREAS, Spectrum is engaged in the development and marketing, sale and licensing of
pharmaceutical products and desires to have access to the IDN 5109 and Indena’s know how relating
to IDN 5109.

     D. WHEREAS, the Parties desire to enter into a license agreement whereby Spectrum shall obtain
the exclusive right to develop and commercialize IDN 5109 as the active ingredient in products for
all uses worldwide.

     NOW, THEREFORE, in consideration of the mutual covenants and conditions set forth herein,
Indena and Spectrum hereby agree as follows:

AGREEMENT

1. DEFINITIONS. In addition to terms defined elsewhere in this Agreement, whenever used
herein the following capitalized terms shall have the meaning set forth below.

     1.1 Affiliate. The term “Affiliate” shall mean any entity which directly or indirectly
controls, is controlled by, or is under common control with Spectrum or Indena, as applicable. The
term “control” as used in this definition means having (i) more than fifty percent (50%) ownership
of the assets, profit interest or outstanding voting securities or (ii) the power to direct or
cause the direction of the management and the
policies of an entity, whether by contract or otherwise.

1

 

     1.2 cGMP. The term “cGMP” means all applicable standards relating to manufacturing practices for
fine chemicals, intermediates, bulk products or finished pharmaceutical products including (i) ICH
Q7a, U.S. cGMP 21CFR Parts 210 & 211, The Rules Governing Medicinal Products in the European
Community, Volume IV Good Manufacturing Practice for Medicinal Products, and the principles
detailed in the Japanese Pharmaceutical Affairs Law and Japanese Ministerial Ordinance 136, as each
may be amended from time to time and (ii) statutes, rules, regulations or guidance documents
(including but not limited to advisory opinions, compliance policy guides and guidelines)
promulgated by any Regulatory Authority having jurisdiction over the manufacture of the Licensed
Compound and the Products.

     1.3 Confidential Information. The term “Confidential Information” shall mean all know-how,
trade secrets and other proprietary or confidential information of a disclosing Party or held by
the disclosing Party, which may be disclosed from one Party to the other Party at any time and from
time to time during the term of this Agreement. “Confidential Information” shall include the terms
of this Agreement as well as any proprietary or confidential information that is jointly owned by
the Parties. Information shall not be considered Confidential Information to the extent such
information:

          (a) is known by the receiving Party at the time of its receipt, and not through a prior
disclosure by the disclosing Party, as documented by business records;

          (b) is properly in the public domain;

          (c) is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so
and is not under an obligation of confidentiality to the disclosing Party; or

          (d) is developed by the receiving party independently of Confidential Information received
from the disclosing Party, as documented by research and development records.

Nothing in this definition shall preclude a Party from use or disclosure of any proprietary or
Confidential Information owned by that Party where the other Party has no rights of ownership.

     1.4 Controlled. The term “Controlled” shall mean possessing the ability to grant a license or sublicense
without violating (i) any applicable law or governmental regulation or (ii) the terms of an
agreement with a Third Party that has an effective date which predates the Effective Date hereof.

     1.5 DMF. The term “DMF” shall mean the documentation submitted to a Regulatory Authority that
is used to provide confidential detailed information about facilities, processes, or articles used
in the manufacturing, processing, packaging, and storing of API for pharmaceutical use.

2

 

     1.6 EMEA. The term “EMEA” shall mean the European Agency for the Evaluation of Medicinal
Products (European Medicines Agency), any successor agency thereto or any equivalent replacement
agency having substantially the same functions.

     1.7 Event of Default. The term “Event of Default” shall have the meaning set forth in
Section 10.3.1 of this Agreement.

     1.8 FDA. The term “FDA” shall mean the United States Food and Drug Administration, or any
successor agency thereto.

     1.9 First Commercial Sale. The term “First Commercial Sale” shall mean, with respect to any
Product, the first sale for end use or consumption of such Product in a country after all required
approvals, including marketing and pricing approvals, have been granted by the governing Regulatory
Authority of such country.

     1.10 GAAP. The term “GAAP” shall mean generally accepted accounting principles in the United
States, in each case as consistently applied by Spectrum or its Affiliates in their respective
financial statements, audited if applicable.

     1.11 IDN 5109. The term IDN 5109 shall mean the compound described in Exhibit A hereto.

     1.12 Improvements.
The term “Improvements” shall mean all inventions, discoveries, enhancements, improvements or
modifications, whether or not patented or patentable, related to the Licensed Compound, a Product
or the Technology, including but not limited to the manufacture, structure, formulation,
conjugation, preparation, dosage, administration or packaging of the Licensed Compound, a Product
or the Technology.

     1.13 IND. The term “IND” shall mean (i) an Investigational New Drug application as defined in
the United States Food, Drug & Cosmetic Act and applicable regulations promulgated thereunder, as
amended from time to time or (ii) an equivalent application or filing with the applicable
Regulatory Authority in any country other than the United States allowing the commencement of human
clinical trials.

     1.14 Joint Inventions. The term “Joint Inventions” shall have the meaning set forth in
Section 4.1 of this Agreement.

     1.15 Joint Patent. The term “Joint Patent” shall mean any Patent filed with respect to a
Joint Invention.

     1.16 Know-How. The term “Know-How” shall mean any discoveries, methods, processes,
techniques, data and technical information that relate to the Licensed Compound, Patent Rights or
the

3

 

Regulatory Filings, now or in the future owned or Controlled by Indena, whether or not: (i) the
same is eligible for protection under the patent laws of the United States or elsewhere; (ii)
enforceable as a trade secret; or (iii) the copying of which would be enjoined or restrained by a
court as constituting unfair competition.

     1.17 License. The term “License” shall have the meaning set forth in Section 2.1.

     1.18 Licensed Compound or “API”. The terms “Licensed Compound” or “API” shall mean the
compound known as IDN 5109 (also known as Ortataxel) and any polymorph, analog or derivative
thereof.

     1.19 Licensed Field. The term “Licensed Field” shall mean all uses (human or otherwise),
including all therapeutic, prophylactic, palliative and diagnostic uses.

     1.20 MAA. The term “MAA” shall mean a Marketing Authorization Application or similar
application filed with the EMEA after completion of human clinical trials to obtain marketing
approval for a Product in the European Union.

     1.21 MHLW. The term “MHLW” shall mean the Ministry of Health, Labour and Welfare in Japan or
any successor agency thereto or any equivalent replacement agency having substantially the same
functions.

     1.22 Milestone Payments. The term “Milestone Payments” shall mean the payments from Spectrum
to Indena under Section 3.1.

     1.23 NDA. The term “NDA” shall mean a New Drug Application, as defined in the United States
Food, Drug & Cosmetic Act and applicable regulations promulgated thereunder, as amended from time
to time, to obtain approval from the FDA for commercial sale of a Product, or an equivalent
application or filing with the applicable Regulatory Authority in any country other than the United
States.

     1.24 Net Sales. The term “Net Sales” shall mean the amount received by Spectrum, its
Affiliates or its sublicensees on account of sales of a Product to Third Parties in the Territory,
less the following deductions to the extent actually allowed or specifically allocated to the
Product by the selling party using GAAP and not separately invoiced: (i) sales and excise taxes and
duties paid or allowed by the selling party and any other governmental charges imposed upon the
production, importation, use or sale of such Product; (ii) customary trade, quantity and cash
discounts allowed on the Product; (iii) allowances or credits to customers on account of rejection
or return of Product or on account of retroactive price reductions affecting such Product; (iv)
freight and insurance costs; (v) rebates, chargebacks and other amounts paid on sale or dispensing
of the Product; (vi) sales commissions paid to

4

 

distributors and/or selling agents; (vii) the booked
cost of devices or systems used for delivering a Product into the patient where the Product when
sold is a combination of the active pharmaceutical ingredient and the device or system; and (viii)
amounts not actually received due to bad debt or returned checks. For the avoidance of doubt, for
each Product the Net Sales shall be calculated only once for the first sale of such Product by
Spectrum, its Affiliate or its sublicensee, as the case may be, to a Third Party which is neither
an Affiliate nor sublicensee of Spectrum. A sale of Products by Spectrum, its Affiliate or its
sublicensee to a wholesaler shall be regarded as the first sale of the Product for the purpose of
calculating Net Sales. Net
Sales shall not include the amount received on account of sales of a Product or of sales of a
Product in a particular country for which the Term of this Agreement has expired.

     1.25 Patent. The term “Patent” shall mean any and all unexpired patents, patent applications,
provisional patent applications and any patent issuing therefrom worldwide, together with any
extensions, registrations, confirmations, reissues, continuations, divisions,
continuations-in-part, reexamination certificates, confirmations, registrations, revalidations,
additions, supplementary protection certificates, substitutions or renewals thereof and any patents
anywhere in the world, claiming the priority date of any of the foregoing.

     1.26 Patent Rights. The term “Patent Rights” shall mean: the Patents set forth on Exhibit
B, all rights (including all U.S. and foreign Patents) arising out of or resulting from each
such Patent, and any other U.S. and foreign Patents, now or in the future owned or Controlled by
Indena having claims covering or directed to the Licensed Compound or the Know-How. The term “Class
A Patents Rights” shall include any and all Patent Rights claiming a Licensed Compound. The term
“Class B Patent Rights” shall include any and all Patent Rights claiming the process to make a
Licensed Compound.

     1.27 Product. The term “Product” shall mean any finished formulation containing the Licensed
Compound as an active ingredient.

     1.28 Regulatory Approval. The term “Regulatory Approval” shall mean the approval, as amended
or modified from time to time, from a Regulatory Authority approving the development, manufacture,
sale or price, as applicable, of Products in a given country.

     1.29 Regulatory Authority. The term “Regulatory Authority” shall mean the principal
governmental organization or agency that has the right to approve the development, manufacture,
sale or, if applicable, the price of Products in a given country, including the FDA, the EMEA and
the MHLW.

     1.30 Regulatory Filings. The term “Regulatory Filings” shall mean all filings with Regulatory
Authorities that relate to the
Licensed Compound or a Product, including Regulatory Approvals.

     1.31 Royalty Term. The term “Royalty Term” shall have the meaning set forth in Section 3.2.2.

5

 

     1.32 Technology. The term “Technology” shall mean the Patent Rights, Know-How and Regulatory
Filings, together with Indena’s interest in any Joint Inventions and any Improvements owned or
Controlled by Indena.

     1.33 Term. The term “Term” shall have the meaning set forth in Section 10.1.

     1.34 Territory. The term “Territory” shall mean all of the countries in the world (including
their territories and possessions).

     1.35 Third Party. The term “Third Party” shall mean any person or entity other than a Party
hereto or an Affiliate.

     1.36 Valid Claim. The term “Valid Claim” shall mean a claim in any unexpired, issued patent
within the Patent Rights which has not been held invalid and/or unenforceable in a decision by a
court or other body of competent jurisdiction from which there is no appeal or, if appealable, from
which no appeal has been taken.

2. LICENSE.

     2.1 License. Indena hereby grants to Spectrum an exclusive (even as to Indena, except as
provided in Section 2.4), right and license under Indena’s rights in and to the Technology to
research, develop, make, have made, use, offer for sale, sell, have sold, distribute, import, and
export the Licensed Compound and/or the Products in the Licensed Field in the Territory (the
“License”).

     2.2 Sublicenses.
Spectrum shall have the right, but not the obligation, to grant sublicenses under the License
to its Affiliates and Third Parties. Each sublicense shall be consistent with the terms of this
Agreement. Spectrum shall remain responsible for the performance of its sublicensees. Spectrum
shall notify Indena of each sublicense granted hereunder.

     2.3 Technology and Material Transfer. On the Effective Date, Indena shall disclose, and as
applicable, provide copies of, all Know-How to Spectrum.

     2.4 Exceptions to Exclusivity. Notwithstanding Section 2.1, Indena retains: (i) the right
under the Technology to manufacture and sell the Licensed Compound and/or the Products exclusively
to Spectrum or Spectrum’s designee in accordance with this Agreement; and (ii) the limited right to
use and license the Patent Rights and Know-How for the manufacture and sale of compounds which do
not contain the Licensed Compound and which are not in competition with the Licensed Compound.
Indena shall keep Spectrum informed of its development efforts with regard to such compounds.

6

 

     2.5 Regulatory Filings. As soon as practicable after the Effective Date, Indena shall assign and
transfer ownership, or have Bayer Corporation (“Bayer”), i.e. Indena’s former licensee whose
license has been terminated to assign and transfer ownership, to Spectrum of any and all Regulatory
Filings. Spectrum shall own all of the Regulatory Filings in perpetuity provided that this
Agreement is not terminated by Spectrum pursuant to Section 10.2 or by Indena pursuant to Sections
10.3 or 10.4, in which case, upon request by Indena, Spectrum shall assign and transfer back to
Indena ownership to all regulatory filings assigned and transferred by Indena (or Bayer) to
Spectrum, on a Product-by-Product and/or country-by-country basis. Spectrum shall have the right
to reference any and all of the data submitted in support of the Regulatory Filings. This right of
reference shall survive expiration or termination of this Agreement for any reason other than for
the same reasons set forth in the preceding sentence. As soon as practicable after the Effective
Date, Indena shall provide copies to Spectrum of all Regulatory Filings, including all
correspondence with appropriate Regulatory Authorities. The upfront payment indicated in Section
3.1 below shall be paid by Spectrum to Indena promptly upon receiving written confirmation that
Indena has performed its obligations under this Section 2.5 relating to the transfer of ownership
of any and all Regulatory Filings and the delivery of copies of all Regulatory Filings.

3. FINANCIAL TERMS AND CONDITIONS.

     3.1 Upfront and Milestone Payments. (a) In consideration of the License and the obligations
assumed by Indena hereunder, Indena shall be entitled to receive from Spectrum the following
amounts:

          (a) [***] Euro (€ [***]) for the license under Class A Patent Rights and the right to refer
to Indena’s DMF;

          (b) [***] Euro (€ [***]) for: (i) the license under Class B Patent Rights; (ii) the right
to use any and all toxicological, pharmacological and clinical data developed by Indena and/or
Bayer relating to the Licensed Compound; and (iii) the transfer of the IND for the Licensed
Compound from Indena or Bayer to Spectrum;

and thus in total the sum of [***] Euros (€ [***]) which shall become due and payable by
Spectrum in installments upon achievement of the following milestones:

	 	 	 	 	 
	 	 	Payment
	 	 	(Euros)
	 
	Upfront	 	 
	As per Section 2.5

	 	(i)
	 	€1,000,000
pursuant to Section
3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€1,000,000
pursuant to Section
3.1(b)

7

 

	 	 	 	 	 
	 	 	Payment
	 	 	(Euros)
	Milestones
	 	 	 	 
	 
	 	 	 	 
	[***] months after the date both of the
following have been achieved: (i) [***]
(consistent with the terms of [***] of this
Agreement) [***], in [***] reasonable opinion,
[***]:

	 	 	 	€ [***] pursuant to
Section 3.1(b)
	 
	 	 	 	 
	At the time the 10th patient is dosed in a Phase 3 clinical trial:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)
	 
	 	 	 	 
	Acceptance of the NDA filing by the FDA in the United States:

	 	 	 	€ [***] pursuant to
Section 3.1(b)
	 
	 	 	 	 
	Approval of the NDA by FDA in the United States:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)
	 
	 	 	 	 
	Acceptance of the MAA filing by the EMEA:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)
	 
	 	 	 	 
	Approval of the MAA filing by the EMEA:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)
	 
	 	 	 	 
	Acceptance of the NDA filing by the MHLW in Japan:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)
	 
	 	 	 	 
	Approval of the NDA by the MHLW in Japan:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)

8

 

	 	 	 	 	 
	 	 	Payment
	 	 	(Euros)
	Annual Net Sales exceed € [***]:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)
	 
	 	 	 	 
	Annual Net Sales exceed € [***]:

	 	(i)
	 	€ [***] pursuant
to Section 3.1(a); and
	 
	 	 	 	 
	 

	 	(ii)
	 	€ [***] pursuant
to Section 3.1(b)

Spectrum shall pay Indena the above payments within thirty (30) days of achieving the milestone (or
thirty (30) days after the Effective Date with regard to the upfront payment). Each of the
foregoing payments shall be paid only one time. Sections 3.1 (a) and (b) are not meant in any way
to limit the License granted by Indena to Spectrum pursuant to Section 2.1

     3.2 Product Royalties.

          3.2.1 Patent Royalties
During the Royalty Term, Spectrum shall pay Indena a royalty rate as set forth in the chart
below on the aggregate annual Net Sales of each Product sold by Spectrum, its Affiliates and any
sublicensees during each calendar year.

	 	 	 
	Annual Net Sales	 	Royalty Rate
	€ [***]

	 	[***]%
	More than € [***] but less than or equal to € [***]

	 	[***]%
	More than € [***]

	 	[***]%

          3.2.2 Royalty Term The “Royalty Term” shall begin on the First Commercial Sale of a
particular Product in a particular country and expire on the earlier of (i) the expiration of the
last Valid Claim covering such Product in that country, as determined on a Product-by-Product basis
and a country-by-country basis or (ii) the regulatory approval of a generic version of a Product in
that country, as determined on a Product-by-Product basis and a country-by-country basis.

          3.2.3 Royalty Offsets In the event that royalty payments are owed by Spectrum to
Third Parties with respect to licenses necessary to use, develop, manufacture or import the
Licensed

9

 

Compound, the royalties owed to Indena under Section 3.2.1 shall be reduced by [***]
Percent ([***]) of the amount of the royalty payments actually paid by Spectrum to such Third
Parties provided that such reductions shall not reduce the royalty paid to Indena in such country
below [***] Percent ([***]%).

     In the event that royalty payments are owed by Spectrum to Third Parties with respect to
licenses necessary to use, develop, manufacture, import or sell a finished formulation of the
Licensed Compound, the royalties owed to Indena under Section 3.2.1 shall be reduced by [***]
Percent ([***]) of the amount of the royalty payments actually paid by Spectrum to such Third
Parties provided that such reductions shall not reduce the royalty paid to Indena in such country
by more than [***] Percent ([***]%) in the aggregate.

          3.2.4 Quarterly Royalty Payments3.2.5 Royalties owed to Indena pursuant to this
Article 3 shall be payable by Spectrum within ninety (90) days after the end of each calendar
quarter (i.e., ninety (90) days after March 31, June 30, September 30 and December 31) based upon
the Net Sales of each Product during such quarter. Any underpayment or overpayment of the
quarterly royalty payments shall be reconciled and added or deducted to the royalty payment due in
the calendar quarter in which such underpayment or overpayment is discovered.  

          3.2.5 Reports Spectrum shall furnish to Indena at the same time as each royalty
payment is made by Spectrum, a written report of Net Sales of the Products on a Product-by-Product
basis and the royalty due and payable thereon, for the quarterly period upon which the royalty
payment is based. Such reports shall be derived from Spectrum’s consolidated financial
statements. 

     3.3 Payments. All payments will be made in immediately available funds in Euros by bank wire
transfer to such bank account designated in writing by Indena from time to time.

     3.4 Records. Spectrum shall keep full, complete and proper records and accounts of all sales
of Products by Spectrum and its Affiliates in accordance with GAAP. All such records, statements,
reports and accounts referred to in this Section 3.4 shall be retained for a period of three (3)
years after the end of the period to which they apply.

     3.5 Income or Other Tax Withholding. If laws, rules or regulations require withholding of
income or other taxes imposed upon payments set forth in this Article 3, Spectrum may make such
withholding payments as required and subtract such withholding payments from the payments set forth
in this Article 3. Spectrum shall submit appropriate proof of payment of the withholding rates to
Indena within a reasonable period of time. Spectrum shall use efforts consistent with its usual
business practices to ensure that any withholding taxes imposed are reduced as far as possible
under the provisions of the current or any future double taxation treaties or agreements between
foreign countries, and the Parties

10

 

shall cooperate with each other with respect thereto, with the
appropriate Party under the circumstances providing the documentation required under such treaty or
agreement to claim benefits thereunder.

     3.6 Audit.
If Indena disagrees with a royalty report provided by Spectrum, with reasonable justification for
such disagreement, Indena, at its own expense, shall have the right, upon reasonable prior notice
during regular business hours, to meet with Spectrum’s independent auditor to inspect and discuss
the books and accounts of Spectrum or its Affiliates, related to the payment and calculation of
royalties arising under this Agreement. After this inspection, if Indena still disagrees with the
report provided by Spectrum, with reasonable justification for such disagreement, Indena, at its
own expense, shall have the right, upon reasonable prior notice during regular business hours, to
appoint independent auditors reasonably acceptable to Spectrum and have them during normal business
hours, inspect and audit the books and accounts of Spectrum or its Affiliates, related to the
payment and calculation of royalties arising under this Agreement. Spectrum shall cooperate and
cause Spectrum’s Affiliates, to cooperate with such auditors. The auditors performing the audit
shall disclose to Indena only information relating to the accuracy of records kept and the payments
made, and shall be under a duty to keep confidential any other information obtained from such
records. If any such audit establishes that Spectrum has underpaid or overpaid the amount due,
Spectrum shall promptly pay any remaining amounts due as established by such audit or Indena shall
promptly refund any over payment. If the underpayment is more than [***] percent ([***]%) of the
aggregate Net Sales for all countries during any calendar year, Spectrum shall reimburse Indena for
its out-of-pocket expense of such audit, together with interest at the rate specified in Section
3.7 below for late payments on any such overdue payment from the date due until paid.

     3.7 Late Payments. Any payments due to Indena under this Agreement that are not paid on the
due date shall accrue interest at the rate of [***] Euro [***].

4. OWNERSHIP AND PATENT MATTERS.

     4.1 Ownership. As between the parties, all Technology provided hereunder by Indena shall be
owned by Indena. Improvements made by an employee, agent or consultant of Spectrum, solely or
jointly with a Third Party, shall be owned by Spectrum. Any Improvements, that are made jointly by
employees, agents or consultants of Spectrum and employees, agents or consultants of Indena (“Joint
Inventions”) shall be jointly owned by Spectrum and Indena and treated as joint inventions under
U.S. laws applicable to joint inventions. Improvements made by an employee, agent or consultant
of Indena, solely or jointly with a Third Party, shall be owned by Indena. Indena hereby grants to
Spectrum, effective after the Agreement expires pursuant to Section 10.1 or Spectrum terminates the
Agreement pursuant to Section 10.3 or 10.4, a perpetual, royalty-free right and license to all
Improvements owned or Controlled by Indena and all information, know-how and other data owned or
Controlled by Indena pertaining to all

11

 

Improvements or
the Joint Inventions. For the avoidance of doubt, the previous sentences shall in no way be
read to modify Sections 2.1 and 5.2 regarding Spectrum’s exclusive (even as to Indena) license to
the Technology. Spectrum shall own any trademarks associated with the Products.

     4.2 Prosecution and Maintenance of Patent Rights.

          4.2.1 Patent Prosecution and Maintenance Spectrum, at its own expense, shall direct
and control the preparation, filing, prosecution and maintenance of all United States and foreign
Patents within the Patent Rights and all Joint Patents, including any interferences and
oppositions. Notwithstanding the foregoing, Indena shall be responsible, at its own expense, for
the re-issue of United States Patent Number 6,906,101 in all countries of the Territory, as
applicable. Indena shall keep Spectrum informed of the re-issue process for this patent.

          4.2.2 Participation and Assistance If requested by Indena, Spectrum shall consult
with Indena with regard to the preparation, filing, prosecution and/or maintenance of the Patents
within the Patent Rights and any Joint Patents. Notwithstanding the preceding sentence, however,
Spectrum shall in all events have final decision-making authority as relates to the preparation,
filing, prosecution and/or maintenance of the Patents within the Patent Rights and any Joint
Patents, and the scope of claims contained therein. Indena shall cooperate fully with Spectrum, at
Spectrum’s request, in all matters relating to the preparation, filing, prosecution and/or
maintenance of the Patents within the Patent Rights and any Joint Patents, including signing any
necessary or appropriate documents, providing written and testimonial evidence, and doing such
other acts as Spectrum may reasonably require.

          4.2.3 Patent Abandonment In the event Spectrum elects not to prosecute or to
discontinue or abandon the prosecution and/or maintenance of any patent or patent application
within the Patent Rights, any such patent or patent application shall at that time be excluded from
the definition of Patent Rights and from the scope of the licenses granted under this Agreement.
Spectrum shall give Indena at least sixty (60) days’ prior written notice of its election to
discontinue or abandon any such patent or patent application within the Patent Rights during which
time Indena may elect, in its sole discretion, to prosecute, file, continue and maintain such
patent or patent application at its sole cost and expense and for its sole benefit by delivery of
written notice to Spectrum. If Indena does not notify Spectrum in writing during such sixty (60)
day period that it is exercising such rights, the patent or patent application shall be deemed
abandoned and neither Indena nor Spectrum shall have any further responsibility for any such
abandoned patent applications or patents. However, if Indena does not elect to prosecute, file,
continue and maintain such
patent or patent application, Spectrum may later elect to continue to prosecute and maintain
such patent or patent application, in which case, the patent or patent application shall remain
within the Patent Rights and License hereunder.

12

 

          4.2.4 Execution of Documents Each Party shall promptly execute or have executed by
its employees, agents and consultants all documents necessary to vest ownership of inventions and
related intellectual property rights relating to Joint Patents in Indena and Spectrum and to enable
Spectrum to file, prosecute and maintain the Patents within the Patent Rights and Joint Patents.
If Spectrum is unable, after reasonable effort, to secure the signature of Indena or any employee,
agent or independent contractor of Indena on any document needed to apply for, prosecute or defend
any patent or other intellectual property right or protection relating to the Patent Rights or the
Joint Patents, Indena hereby designates and appoints Spectrum and its duly authorized officers and
agents as its agent and attorney in fact to execute, verify and file applications, and to do all
other lawfully permitted acts necessary to protect Spectrum’s rights in Joint Patents and to enable
Spectrum to file, prosecute and maintain Patent Rights and Joint Patents with the same legal force
and effect as if executed by Indena.

     4.3 Infringement Actions.

          4.3.1 Prosecution of Infringement

               (a) The Parties shall promptly notify one another in writing of any and all actual or
threatened infringements by Third Parties of any Patents within the Technology that relate to a
Product in the Licensed Field that is known to them, and in any event within thirty (30) days of
learning of such infringement.

               (b) With respect to actual or threatened infringements of Patents within the Technology with
respect to the Products, Spectrum shall have the first right, but not the obligation, to file suit
or take other action to prevent such infringements of any such Patents. To the extent Spectrum
takes such action, Spectrum shall control any such action and may enter into settlements,
stipulated judgments or other arrangements respecting such infringement, at its own expense;
provided, however, that such proposed settlements, judgments or arrangements shall be subject to
Indena’s consent, not to be unreasonably withheld. In the event that Spectrum takes such action,
Spectrum shall indemnify, defend and hold Indena harmless from any costs, expenses and liabilities
respecting the action for such claimed infringement. Indena shall permit an action to be brought
by Spectrum in Indena’s name if required by law. Indena agrees to provide all assistance that
Spectrum may reasonably require in any litigation, including providing written evidence, deposition
and trial testimony, for which Spectrum shall pay to Indena a reasonable and customary hourly rate
of compensation. Spectrum shall keep Indena informed
of developments in any such action, including, to the extent permissible by law, the status of
any settlement negotiations and the terms of any offer related thereto. Indena shall have the
right at its own expense to be represented by counsel in any such action. Any damages or other
recovery from an infringement action undertaken by Spectrum pursuant to this Section 4.3.1(b) shall
[***].

13

 

               (c) Spectrum shall promptly notify Indena in writing of its intention with regard to any such
infringement. In the event that Spectrum elects not to take action against an actual or threatened
infringement, Indena shall have the right to take action against such infringement, in which case
Indena shall (i) pay any and all costs and expenses incurred in such action, (ii) indemnify, defend
and hold Spectrum harmless from any costs, expenses or liability respecting all such action, and
(iii) retain any and all recovery from such action. Spectrum agrees to provide all assistance that
Indena may reasonably require in any litigation, including providing written evidence, deposition
and trial testimony, for which Indena shall pay to Spectrum a reasonable hourly rate of
compensation.

          4.3.2 Defense of Infringement Claims

               (a) If a Third Party makes or threatens against Spectrum, its Affiliates or sublicensees any
claim of infringement of a Patent right based upon the use of, or arising as a result of the
exercise of the rights and licenses granted hereunder to the Technology (each an “Alleged
Infringement”), Spectrum shall have the right to respond to and defend any and all such Alleged
Infringements at its own cost and expense, and in its sole discretion. Indena agrees to provide
any necessary assistance that Spectrum may reasonably require in any such defense action for which
Spectrum shall pay to Indena a reasonable hourly rate of compensation. Indena shall have the
right, at its own expense, to retain counsel of its choice to represent it in any such defense
action.

               (b) Spectrum shall promptly notify Indena in writing and provide a copy of (i) any claim of
Alleged Infringement filed with a court or governmental authority or (ii) any written notice of an
Alleged Infringement from an attorney or law firm. Within a reasonable period of time in advance
of any responsive deadline required by law or otherwise set forth in the claim or notice of Alleged
Infringement, Spectrum shall notify Indena in writing as to whether or not Spectrum intends to
respond to such Alleged Infringement. In the event that Spectrum does not intend to respond to any
such claim or notice or, notwithstanding Section 4.3.2(a), and notifies Indena in accordance with
this Section, Indena shall have the right, in its sole discretion, to respond to such Alleged
Infringement, in which case Indena shall pay any and all future costs and expenses incurred by
Spectrum in such action, and shall indemnify, defend and hold Spectrum harmless from any future
costs, expenses or liability respecting all such actions undertaken by Indena.

5. OBLIGATIONS RELATED TO SUPPLY, DEVELOPMENT, MARKETING AND COMMERCIALIZATION.

14

 

     5.1 Spectrum’s Diligence Obligations. Spectrum, its Affiliates and/or sublicensees, as
applicable, shall use commercially reasonable efforts to (i) complete, file and pursue Regulatory
Approval for one or more Products in the Territory and (ii) promote and market the Product or
Products in the Territory. Such development, marketing and commercialization shall be pursued at
such party’s sole cost and expense. Spectrum, its Affiliates and/or sublicensees, as applicable,
shall have sole responsibility for making all decisions regarding the development, marketing and
commercialization of the Products.

     5.2 Research and Development. Indena shall not conduct or sponsor any research or development
with respect to the Licensed Compound without the prior written consent of Spectrum.

     5.3 Governmental Approvals. Spectrum, its Affiliates and/or sublicensees, as applicable,
shall be solely responsible for obtaining all necessary approvals from Regulatory Authorities for
the use, development, production, distribution, sale and import or export of any Products, at such
parties expense, including preclinical and clinical trials and Regulatory Filings. Spectrum, its
Affiliates and/or sublicensees, as applicable, shall have sole responsibility for any warning
labels, packaging and instructions as to the use of Products. Spectrum, its Affiliates and/or
sublicensees shall own all Regulatory Filings made with the applicable Regulatory Authorities with
respect to the Products and all regulatory approvals.

     5.4 Supply of API. Subject to the provisions set out below in this Section 5.4, Indena shall
[***] supply and Spectrum shall purchase [***] from Indena [***] Spectrum’s, its Affiliates’ and/or
sublicensees’, [***] API [***] the Product at a price of € [***] per gram subject to adjustment
for the reasons specified in this Section 5.4. The Parties shall in good faith negotiate the terms
of a supply agreement and a quality agreement for [***] supply of the API. The provisions of such
agreements shall be consistent with the provisions set forth in this Section 5.4 and the term of
such agreements shall survive the termination or expiration of this Agreement, subject to standard
termination provisions, including a unilateral right to terminate by Spectrum.

     Each shipment of API shall be accompanied by a Certificate of Analysis and Compliance in a
form mutually agreed by the Parties, signed by Indena’s designated quality manager, that sets forth
the
analytical test results against the specifications for a lot of API and that certifies that
such lot was produced and tested in compliance with the specifications, cGMPs, and all applicable
Regulatory Approvals. [***].

15

 

     If Spectrum, its Affiliates and/or sublicensees, as applicable, engage a Third Party to
manufacture the API, upon written request by Spectrum, Indena will provide technical assistance to
the manufacturer engaged by Spectrum, its Affiliates and/or sublicensees, as applicable. The [***]
of technical assistance shall be provided at [***] (other than for [***] from an Indena facility at
Spectrum’s request) and any additional technical assistance shall be provided at € [***].

     If Spectrum, its Affiliates and/or sublicensees, as applicable, receive a bona fide offer from
a qualified Third Party to supply API at a price lower than € [***] per gram and upon terms
comparable to those applicable to current supplies by Indena, then the Parties shall take the steps
provided for in the supply agreement between the Parties.

     Upon request by Spectrum, Indena shall supply to Spectrum, to a location Spectrum designates,
an amount of API, as reasonably determined by Spectrum, necessary for Spectrum to conduct Phase 2
clinical trials.

6. INDEMNITY.

     6.1 Spectrum Indemnification. Spectrum (the “Indemnifying Party” under this Section 6.1)
hereby agrees to indemnify, defend and hold Indena, its Affiliates, and its directors, employees
and agents (the “Indemnified Party(ies)” under this Section 6.1) harmless from and against any and
all suits, claims, actions, demands, liabilities, expenses and/or loss, including reasonable legal
expenses and attorneys’ fees (collectively, “Losses”), to which one or more Indemnified Parties may
become subject as a result of any (a) claim, demand, action or other proceeding for personal
injury, wrongful death or product defect by any Third Party relating to the research, development,
manufacture, use or sale of Products by Indemnifying Party and/or its Affiliates and/or their
respective employees or agents, except to the extent that such Losses result from the gross
negligence, wrongful intentional acts or willful omissions of Indemnified Party(ies), (b) claim,
demand, action or other proceeding by any Third Party to the extent such Losses result from
Spectrum’s material breach of any, obligation, representation, warranty or covenant contained in
this Agreement or (c) any
failure by Spectrum or its Affiliates or its sublicensees to comply with applicable law. In
no event shall Spectrum be liable for any lost opportunities, profits or special, incidental,
consequential or indirect damages of the Indemnified Party(ies) under this Section 6.1, except,
however, as the result of any breach by Spectrum of the covenants in Article 8 below.

     6.2 Indena Indemnification. Indena (the “Indemnifying Party” under this Section 6.2) hereby
agrees to indemnify, defend and hold Spectrum and its Affiliates and their directors, officers,
employees, and agents (the “Indemnified Party(ies)” under this Section 6.2) harmless from and
against any Losses

16

 

to which one or more Indemnified Parties may become subject as a result of any (a) claim, demand,
action or other proceeding by any Third Party to the extent such Losses result from Indena’s breach
of any material obligation, representation, warranty or covenant contained in this Agreement or (b)
failure by Indena to comply with applicable law. In no event shall Indena be liable for any lost
opportunities, profits or special, incidental, consequential or indirect damages of the Indemnified
Party(ies) under this Section 6.2., except, however, as the result of any breach by Indena of any
of the covenants in Article 8 below.

     6.3 Indemnity Procedure.

               (a) The Indemnified Party(ies) agrees to give the Indemnifying Party(ies) written notice, as
soon as is practicable, but in any event within thirty (30) days if possible, of any claim, suit,
loss or the discovery of facts upon which such Indemnified Party(ies) intends to base a request for
indemnification under Section 6.1 or Section 6.2 (collectively, a “Claim”).

               (b) The Indemnified Party(ies) shall furnish promptly to the Indemnifying Party(ies) copies of
all papers and official documents received in respect of any Claim. The Indemnified Party(ies)
shall cooperate with the Indemnifying Party(ies), at the Indemnifying Party(ies)’s expense, in
providing witnesses and records necessary in the defense against any Claim.

               (c) With respect to any Claim relating solely to the payment of money damages that will not
(i) result in the Indemnified Party(ies)’s becoming subject to injunctive or other relief, (ii)
require an admission of guilt or other responsibility or liability, or (iii) otherwise adversely
affect the business interests or rights of the Indemnified Party(ies) in any manner, and as to
which the Indemnifying Party(ies) shall have acknowledged in writing the obligation to indemnify
the Indemnified Party(ies) hereunder, the Indemnifying Party(ies) shall have the sole right to
defend, settle, or otherwise dispose of
such claim, on such terms as the Indemnifying Party(ies), in its sole discretion (subject to
the limitations of this Section), shall deem appropriate.

               (d) With respect to all other Claims the Indemnifying Party(ies) shall obtain the written
consent of the Indemnified Party(ies), which shall not be unreasonably withheld, prior to ceasing
to defend, settling, or otherwise disposing thereof.

               (e) The Indemnifying Party(ies) shall not be liable for any settlement or other disposition of
a Claim by the Indemnified Party(ies) that is reached without the written consent of the
Indemnifying Party(ies).

               (f) Except as provided above, the costs and expenses, including fees and disbursements of
counsel, incurred by any Indemnified Party(ies) in connection with any claim shall be

17

 

paid by the
Indemnifying Party(ies), without prejudice to the Indemnifying Party(ies)’s right to contest the
Indemnified Party(ies)’s right to indemnification and subject to refund in the event the
Indemnifying Party(ies) is ultimately held not to be obligated to indemnify the Indemnified
Party(ies).

               (g) The Indemnified Party(ies) shall always have the right to retain counsel and participate
in the defense, negotiation or settlement of any Claim at its/their own cost and expense.

7. REPRESENTATIONS AND WARRANTIES.

     7.1 By Indena.

     Indena hereby represents and warrants that as of the Effective Date:

               (a) It is a financially solvent company duly organized, validly existing and in good standing
under the laws of its jurisdiction of formation.

               (b) This Agreement is a legal and valid obligation of Indena, binding upon Indena and
enforceable against Indena in accordance with the terms of this Agreement, except as such
enforceability may be affected by laws affecting creditors’ rights generally and general equitable
principles. The execution, delivery and performance of this Agreement by Indena does not conflict
with any agreement, instrument or understanding, oral or written, to which Indena is a party or by
which Indena may be bound, or violate any law or regulation of any court, governmental body or
administrative or other agency having authority over Indena. All consents, approvals and
authorizations from all governmental authorities or other Third Parties required to be obtained by
Indena in connection with the execution, delivery and performance of this Agreement have been
obtained.

               (c) (A) it has all necessary right and authority to execute, deliver and perform all of its
obligations under this Agreement, which actions have been duly and validly authorized and approved
by all necessary corporate action of Indena; (B) it has the right to grant the licenses and other
rights granted herein; (C) it has not previously granted any right, license or interest in or to
the Technology, or any portion thereof, inconsistent with the rights granted to Spectrum herein;
and (D) to the best of its knowledge, there are no material adverse proceedings, claims or actions
pending or threatened relating to the Technology which would materially interfere with Indena’s
performance of its obligations or power to make the grants and covenants hereunder, or Spectrum’s
unfettered use of the Technology.

               (d) Indena is the owner of all right, title and interest in and to all of the Technology. The
Technology is free and clear of any and all encumbrances, covenants, conditions and restrictions
or, other adverse claims or interests of any kind or nature, including but not limited to,
financial and technical, and Indena has not received any oral or written notice or claim
challenging its complete

18

 

and exclusive rights to the Technology or suggesting that any other person
has any claim of legal or beneficial ownership with respect thereto, and there is no agreement,
decree, arbitral award or other provision or contingency in effect in which Indena has granted
licenses in the Technology or in which Indena is obligated to grant licenses in the Technology.

               (e) To Indena’s best knowledge, it owns or possesses sufficient rights to use all of the
Technology necessary to develop, make, have made, use, sell, offer for sale, have sold, import and
export and commercialize the Licensed Compound in the Licensed Field in the Territory.

               (f) The license agreement with Bayer has been terminated in its entirety and Bayer has no
rights in any way to the Technology.

               (g) It has provided copies to Spectrum of all Know-How, as applicable, and all Regulatory
Filings, including all correspondence with appropriate Regulatory Authorities.

               (h) No litigation is now pending and no notice or other claim has been received by Indena,
(A) alleging that Indena has engaged in any activity or conduct that infringes upon, violates or
constitutes the unauthorized use of any Patents of any Third Party, or (B) challenging the
ownership, use, validity or enforceability of any of the Patents Rights. In addition, Indena is
not aware of any unasserted claim or demand which it believes can be enforced by a Third Party
against any the Patent Rights.

               (i) The Technology was not obtained by Indena in violation of any contractual or fiduciary
obligation to which Indena or any of its respective employees are or were bound, or by the
misappropriation of the trade secrets of any Third Party.

               (j) To the best of Indena’s knowledge and belief, all of the data and information that Indena
has provided to Spectrum prior to the Effective Date relating to the Technology, and to IDN 5109 in
general, are reasonably accurate, and Indena has not omitted therefrom any material data or
information in Indena’s possession or control reasonably in advance of the Effective Date
concerning the same.

               (k) The Patent Rights are in full force and effect and are in compliance with all legal
requirements regarding the filing, examination, and maintenance fees. Indena has not taken any
action or, failed to take any action (including a failure to disclose material prior art in
connection with the prosecution of any patent), or used or enforced or, failed to use or enforce
any of the Patents Rights in a manner that would result in the abandonment or unenforceability of
any of the Patents Rights.

               (l) No Patent Rights have been or are now involved in any interference, reissue, reexamination
or opposing proceeding in any jurisdiction within the Territory. To Indena’s best

19

 

knowledge, no
such action has been threatened. There is no patent of any person that claims the same subject
matter as the Patent Rights, and Indena is not aware of any prior art that invalidates any claim
within the Patent Rights.

               (m) To Indena’s best knowledge, the use of the Patents Rights to develop, make, have made,
use, sell, offer for sale, have sold, import and export and commercialize the Licensed Compound in
the Licensed Field in the Territory, would not infringe upon, violate or constitute the
unauthorized use of any rights owned or controlled by any Third Party, including any Patent of any
Third Party.

               (n) To Indena’s best knowledge, no Third Party is misappropriating, infringing, diluting or
violating any of the Patent Rights, and no claims for any of the foregoing have been brought
against any Third Party by Indena. Indena has taken reasonable steps in accordance with normal
industry practice to protect its Patent Rights.

               (o) The chemical structure described in Exhibit A is the correct chemical structure of IDN
5109.

     7.2 By Spectrum.

     Spectrum hereby represents and warrants that as of the Effective Date:

               (a) (A) it is a financially solvent corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware; (B) it has the full right, authority and power to
enter into this Agreement and to perform its obligations hereunder, which actions have been
duly and validly authorized and approved by all necessary corporate action of Spectrum; (C) the
execution, delivery and performance of this Agreement have been duly authorized by all necessary
corporate action on the part of Spectrum; and (D) to the best of its knowledge there are no
material adverse proceedings, claims or actions pending or threatened against it which would
materially interfere with the performance of its obligations hereunder.

               (b) This Agreement is a legal and valid obligation of Spectrum, binding upon Spectrum and
enforceable against Spectrum in accordance with the terms of this Agreement, except as such
enforceability may be affected by laws affecting creditors’ rights generally and general equitable
principles. The execution, delivery and performance of this Agreement by Spectrum does not conflict
with any agreement, instrument or understanding, oral or written, to which Spectrum is a party or
by which Spectrum may be bound, or violate any law or regulation of any court, governmental body or
administrative or other agency having authority over Spectrum. All consents, approvals and
authorizations from all governmental authorities or other Third Parties required to be obtained by

20

 

Spectrum in connection with the execution, delivery and performance of this Agreement have been
obtained.

8. ADDITIONAL COVENANTS.

     8.1 Preservation of Title. Indena shall use its best efforts to preserve and maintain its
ownership and title to all Technology licensed hereunder.

     8.2 No Conflicts. Neither Party shall grant any right, license or interest in or to the
Technology, or any portion thereof, inconsistent with the rights granted to Spectrum herein.
Without the other Party’s prior written consent, neither Party shall enter into any agreement that
creates additional obligations upon the other Party or limits the exercise of the other Party’s
rights hereunder or diminishes the other Party’s rights hereunder.

9. CONFIDENTIALITY AND PUBLICATION.

     9.1 Treatment of Confidential Information. The Parties agree that during the term of this
Agreement, and for a period of seven (7) years after this Agreement terminates or expires, a Party
receiving Confidential Information of the other Party will (i) maintain in confidence such
Confidential Information to the same extent such Party maintains the
confidentiality of its own Confidential Information, (ii) not disclose such Confidential
Information to any Third Party without the prior written consent of the disclosing Party and (iii)
not use such Confidential Information for any purpose other than the exercise of a Party’s rights
or performance of a Party’s obligations under this Agreement; provided however, that the provisions
of this Section 9.1 shall not prevent a Party from disclosing Confidential Information if such
disclosure:

               (a) is made to its employees, directors, accountants, attorneys, contractors or consultants
who reasonably require such disclosure on a need to know basis and who are bound to it by
obligations of confidentiality and non-use no less stringent than the obligations between Spectrum
and Indena hereunder;

               (b) is made to collaborators for the purpose of performing the obligations or exercising the
rights of a Party hereunder and who are bound to that Party by obligations of confidentiality and
non-use no less stringent than the obligations between Spectrum and Indena hereunder;

               (c) is in response to a valid order of an United States court or otherwise required by law or
regulation, provided however that receiving Party shall first have given notice to the disclosing
Party and shall have made a reasonable effort to obtain a protective order by: (i) seeking
protection of Confidential Information not relevant to the court’s inquiry from a general
disclosure (e.g., without

21

 

limitation, requesting limited and in-camera review by such court and/or
seeking that such information be treated under seal); (ii) seeking to redact any Confidential
Information; and (iii) in any event requiring that, to the extent ordered to be disclosed, that
such disclosure of Confidential Information be used only for the purposes for which the order was
issued; or

               (d) is necessary to: (i) file or prosecute Patents in accordance with this Agreement; (ii)
submit regulatory filings with respect to Products in accordance with this Agreement; (iii)
prosecute or defend litigation; (iv) make required governmental securities filings and other such
similar and required disclosures by law, subject to appropriate redactions and requests for
confidential treatment as permitted by law; (v) make disclosures required by the principal stock
exchange on which the Party’s stock is traded, subject to appropriate redactions and requests for
confidential treatment as permitted by law and the rules of such exchange; (vi) conduct
pre-clinical or clinical trials of Products in accordance with this Agreement, provided any
Affiliates or Third Parties conducting pre-clinical trials agree to be bound by terms of
confidentiality and non-use at least equivalent in scope to those set forth in this Section 9.1 and
any Affiliates or Third Parties conducting clinical trials agree to be bound by terms of
confidentiality and non-use that are customarily obtained in connection with such clinical trials;
or (viii) enable Affiliates or bona fide potential or actual sublicensees to evaluate and/or
exercise their rights under a sublicense that would be or has been issued in accordance with this
Agreement, provided such
Affiliates and Third Parties agree to be bound by similar terms of confidentiality and non-use
at least equivalent in scope to those set forth in this Section 9.1.

     9.2 Public Statements.

          9.2.1 Publications Indena or Spectrum, as the case may be, may publish or present
information derived from the performance of this Agreement, provided that: the publishing Party
first provides the non-publishing Party with a copy of a proposed manuscript for comment and input
at least twenty (20) days prior to any submission to the publisher and a copy of an abstract for
comment and input at least ten (10) days before submission to the Third Party organization. In
addition, at the non-publishing Party’s request, the publishing party will further delay the
presentation or publication for an additional ten (10) days so as to allow the non-publishing party
time to file for patent protection or other intellectual property protection. If a publication by
Spectrum results from work relating to the Technology, Spectrum agrees to acknowledge Indena and
give credit to Indena’s scientists, as scientifically appropriate, based on any contribution they
may have made to the work. Likewise, if a publication by Indena results from work performed by
Spectrum, Indena agrees to acknowledge Spectrum and give credit to Spectrum’ scientists, as
scientifically appropriate, based on any contribution they may have made to the work.

          9.2.2 Other Public Statements Except as provided in Section 9.2.1, or as otherwise
required by law or the rules of the principal stock exchange on which the Party’s stock is traded,
no Party

22

 

shall originate any public statement, news release or other written public announcement,
whether in the public press, stockholders’ reports, or otherwise, relating to this Agreement or to
any sublicense hereunder, or to the performance hereunder or any such agreements, or use a Party’s
name for any purpose, including in connection with the advertising or sale of Products, without the
prior written approval of the other Party, such consent not to be unreasonably withheld. The
Parties each agree to respond to each such request within five (5) business days of receipt of a
request (unless a shorter period of time is necessary to comply with law). Notwithstanding
anything to the contrary in this Agreement, each party shall be permitted to publicly disclose (i)
the existence of this Agreement, (ii) that Indena and Spectrum are the parties to this Agreement,
and (iii) the Technology covered by this Agreement. In the case of unintentional public disclosure
concerning this Agreement, any Product or any other subject matter hereof, the disclosing Party
shall promptly inform the other Party of such disclosure and the other Party shall be entitled to
make a public announcement regarding the subject matter of the disclosure. The other Party shall
notify the disclosing Party of their intention to make such an announcement. Following a Party’s
consent to or approval of the public announcement of any information pursuant to this Section
9.2.2, both Parties shall
be entitled to make subsequent public announcements of such information without renewed
compliance with this Section 9.2.2, unless the scope and/or duration of such consent or approval is
expressly limited. Upon conclusion of this Agreement, the Parties will publish a press release on
their future cooperation.

10. TERM, DEFAULT AND TERMINATION.

     10.1 Term of Agreement. The term of this Agreement shall commence on the Effective Date and,
unless terminated early in accordance with the provisions of this Agreement, shall continue on a
Product-by-Product and country-by-country basis until the expiration of the obligation to pay
royalties under Section 3.2 above applicable to such Product in such country (the “Term”). This
Agreement shall expire in its entirety after the date that Spectrum no longer owes any royalties to
Indena under Section 3.2.

     10.2 Unilateral Termination – Spectrum. Spectrum shall have the unilateral right to terminate
this Agreement, in its entirety or on a Product-by-Product and/or country-by-country basis, at any
time for any reason.

     10.3 Default.

          10.3.1 The following event shall constitute an “Event of Default” hereunder: a material
breach of a material provision of this Agreement by a Party, and the failure of the Party in breach
to cure such material breach within ninety (90) days after receipt of notice from the other Party
specifying in reasonable detail the nature of such breach (the “Termination Notice”). For purposes
of this Agreement,

23

 

it is not a “material breach” of this Agreement by Spectrum if the development
of a Product is delayed due to the following: (i) reasonable scientific, medical or technical
reasons; (ii) circumstances that are beyond the control of Spectrum; or (iii) the fault of Indena.
In addition, in the event of a Dispute (as defined in Section 11.1) between the Parties as to
whether a payment is owed hereunder, then such Dispute shall be resolved in accordance with Article
11 and the applicable cure period shall be tolled (even if such period has already expired) during
the pendency of such resolution.

          10.3.2 Upon the occurrence of any Event of Default by a Party, the non-defaulting Party may
deliver to the defaulting Party a Termination Notice and without need of a further notice, such
termination to be effective ninety (90) days after the date of receipt of the Termination Notice,
unless the Party in breach cures the breach to the reasonable satisfaction of the terminating Party
during said ninety (90) days period. Such termination rights shall be in addition to and not in
substitution for any other remedies that may be available to the non-defaulting Party. Termination
pursuant to this Section 10.3.2 shall not be treated as an election of remedies and shall not
relieve the defaulting Party from liability and
damages to the other Party for breach of this Agreement. Waiver by either Party of a single
breach or a succession of breaches shall not deprive such Party of any right to terminate this
Agreement arising by reason of any subsequent breach.

     10.4 Insolvency. In addition to the termination rights provided for in this Section, each
Party shall have the right to terminate this Agreement, immediately by giving written notice of
termination to the other Party, if the other Party files a voluntary petition, or if an involuntary
petition is granted in respect of the other Party and appeal proceedings are not commenced within a
period of fifteen (15) days from the date of such petition under the bankruptcy provisions of
applicable law, or the other Party is declared insolvent, undergoes voluntary or involuntary
dissolution, or makes an assignment for the benefit of its creditors, or fails or is unable to pay
its debts as they come due, or suffers the appointment of a receiver or trustee over all, or
substantially all, of its assets or properties. All rights and licenses granted under or pursuant
to this Agreement by Indena are, for the purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
Code. The Parties agree that Spectrum shall retain and may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code.

     10.5 Effects of Expiration or Termination

               (a) Rights Upon Expiration. Following the expiration of this Agreement with respect
to a Product in a country in the Territory pursuant to Section 10.1, Spectrum shall have and retain
a perpetual, royalty-free, fully paid up License for such Product in such country, however,
Spectrum’s obligations under this Agreement with respect to such Product in such country in the
Territory shall terminate. Following the expiration of the term of this Agreement in its entirety
pursuant to Section 10.1,

24

 

Spectrum shall have and retain a perpetual, royalty-free, fully paid up
License for the Licensed Compound in all countries in the Territory, however, Spectrum’s
obligations under this Agreement shall terminate. In addition, Spectrum shall retain all rights
and interest in all materials, inventions, discoveries and know-how (whether or not patentable or
patented) solely generated by Spectrum in the course of performing research and development
activities under the licenses granted in this Agreement. Other than rights intended to survive
expiration, or as otherwise provided under Section 10.5(e), neither Party shall have any further
rights or obligations upon the expiration of this Agreement in its entirety.

               (b) Rights Upon Termination by Indena Under Sections 10.3 or 10.4 or by Spectrum Under
Section 10.2. Upon any termination of this Agreement by Indena under Section 10.3 or 10.4 or
by Spectrum under Section 10.2, all rights and licenses granted by Indena to Spectrum shall
terminate and revert to Indena and, subject to clause (e) below, Spectrum’s obligations under
this Agreement shall terminate. The foregoing provisions shall also apply to the partial
termination of this Agreement by Spectrum on a Product-by-Product and/or country-by-country basis
in accordance with Section 10.2, provided, however, that in such event only those rights that
solely pertain to the Product and/or country being terminated would revert back to Indena and
Spectrum’s obligations under this Agreement only with respect to such Product in such country shall
terminate. In addition, Spectrum shall provide to Indena all CMC data, preclinical testing and
stability data and results and clinical trial data and results relating to the development of
Products and a technology transfer package for all processes, formulations, and protocols for the
manufacture of Products. If Spectrum has licensed any technology from Third Parties relating to
the Technology or any Product, Spectrum shall use commercially reasonable efforts to transfer such
rights to Indena at no cost to Indena. Notwithstanding the foregoing, Spectrum shall retain its
right, title and interest under Section 4.1 in any Improvements made solely by Spectrum and in any
Joint Inventions and hereby grants to Indena effective upon termination of this Agreement by
Spectrum pursuant to Section 10.2 a non-exclusive, perpetual, royalty-free right and license to any
Improvements made solely by Spectrum and to any Joint Inventions.

               (c) Rights Upon Termination by Spectrum under Sections 10.3 or 10.4. Upon any
termination of this Agreement by Spectrum under Sections 10.3 or 10.4, the license rights granted
by Indena to Spectrum contained in this Agreement shall continue in full force and effect, provided
however, that, subject to clause (e) below, Spectrum’s obligations under this Agreement shall
terminate. Notwithstanding the foregoing, Indena shall retain its right, title and interest under
Section 4.1 in any Joint Inventions and in any Improvements made by Indena solely or jointly with a
Third Party.

               (d) Payments. Not later than ninety (90) days after the expiration or termination
date of this Agreement in its entirety, each Party shall pay to the other Party any amounts that
are then due and payable, including any final period royalty report and payment.

25

 

               (e) Accrued Rights; Surviving Obligations. Termination (partially or completely) or
expiration of this Agreement for any reason shall be without prejudice to any rights which shall
have accrued to the benefit of either Party prior to such termination or expiration, and shall not
relieve either Party from its obligations which are expressly indicated to survive expiration or
termination of this Agreement, including those under Articles 1, 6, 9, 11 and 12 and Sections 4.1,
4.2, 5.4, 10.5 and 10.6 which shall survive any expiration or termination of this Agreement.
Spectrum shall have no liability for financial obligations that accrue after the date of
termination or expiration of this Agreement, including but not limited to the milestone payments
payable pursuant to Section 3.1. For the avoidance of doubt, if Spectrum terminates this Agreement
pursuant to Section 10.2 [***].

26

 

     10.6 Work-in-Progress. Notwithstanding anything in this Agreement to the contrary, upon any
such early termination of the license granted hereunder in accordance with this Agreement, Spectrum
shall be entitled to finish any work-in-progress and to sell any completed inventory of a Product
which remain on hand as of the date of the termination, so long as Spectrum pays to Indena the
royalties applicable to said subsequent sales in accordance with the terms and conditions as set
forth in this Agreement, provided that no such sales shall be permitted after the expiration of
[***] after the date of termination.

11. DISPUTE RESOLUTION.

     11.1 Arbitration. Without prejudice to the provisions of Section 11.4 below, any claim,
dispute, or controversy of any nature arising out of or relating to this Agreement, including any
action or claim based on tort, contract or statute, or concerning the interpretation, effect,
termination, validity, performance and/or breach of this Agreement (each, a “Dispute”) between the
Parties shall be finally settled by binding arbitration conducted in the English language in
accordance with the Rules of the International Chamber of Commerce (“ICC”). The arbitration shall
be held in Paris, France, if the demand for arbitration is filed by Spectrum, and New York, New
York, if the demand for arbitration is filed by Indena, and shall be conducted by three (3)
arbitrators who are knowledgeable in the subject matter at issue in the dispute. One (1)
arbitrator will be selected by Indena, one (1) arbitrator will be selected by Spectrum, and the
third arbitrator will be selected by mutual agreement of the two (2) arbitrators selected by the
Parties, provided that if a Party fails to select an arbitrator within thirty (30) days of the
request for arbitration, the arbitrator that was to be selected by such Party shall be appointed in
accordance with the rules of the ICC. The arbitrators may proceed to an award, notwithstanding the
failure of either Party to participate in the proceedings. The arbitrators shall issue a written
award and statement of decision describing the essential findings and conclusions on which the
award is based, including the calculation of any damages awarded. The arbitrators shall be
authorized to award compensatory damages, but shall NOT be authorized to (i) award non-economic or
punitive damages (except to the extent expressly permitted by this Agreement), or (ii) reform,
modify or materially change this Agreement or any other agreements contemplated hereunder;
provided, however, that the damage limitations described in part (i) of this sentence will not
apply if such damages are statutorily imposed. The arbitrators also shall be authorized to grant
any temporary, preliminary or permanent equitable remedy or relief that the arbitrators deem just
and equitable and within the scope of this Agreement, including an injunction or order for specific
performance. The award of the arbitrators shall be the sole and exclusive remedy of the Parties.
Judgment on the award rendered by the arbitrators may be enforced in any court having
competent jurisdiction thereof, subject only to revocation on grounds of fraud or clear bias on the
part of the arbitrators.

27

 

     11.2 Administration. Each Party shall bear its own attorneys’ fees, costs, and disbursements
arising out of the arbitration, and shall pay an equal share of the fees and costs of the
arbitrators; provided, however, that the arbitrators shall be authorized to determine whether a
Party is the prevailing party, and if so, to award to that prevailing party reimbursement for its
reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness fees
and expenses, photocopy charges and travel expenses), and/or the fees and costs of the arbitrators.
Absent the filing of an application to correct or vacate the arbitration award (if permitted by
ICC rules), each Party shall fully perform and satisfy the arbitration award within fifteen (15)
days of the service of the award.

     11.3 Waivers. By agreeing to the binding arbitration provision in Section 11.1, the Parties
understand that they are waiving certain rights and protections which may otherwise be available if
a Dispute between the Parties were determined by litigation in court, including the right to seek
or obtain certain types of damages precluded by this provision, the right to a jury trial, certain
rights of appeal, and a right to invoke formal rules of procedure and evidence.

     11.4 Non-Arbitrable Disputes. Section 11.1 shall not apply to any dispute, controversy or
claim that concerns (A) the validity, enforceability or infringement of a Patent, trademark or
copyright; or (B) any antitrust, anti-monopoly or competition law or regulation, whether or not
statutory. All such disputes, controversies or claims, and all judicial actions brought in order
to enforce the instituting Party’s rights hereunder through specific performance, injunction or
similar equitable relief, shall be brought before any court having jurisdiction.

12. GENERAL PROVISIONS.

     12.1 Further Assurances. At any time or from time to time on and after the Effective Date,
each Party, at the request of the other Party, shall (i) deliver to the other Party such records,
data or other documents consistent with the provisions of this Agreement, (ii) execute, and deliver
or cause to be delivered, all such assignments,
consents, documents or further instruments of transfer or license, and (iii) take or cause to
be taken all such other actions, as the other Party may reasonably deem necessary or desirable in
order for such other Party to obtain the full benefits of this Agreement and the transactions
contemplated hereby.

     12.2 Independent Contractors. The relationship between Indena and Spectrum is that of
principal to principal. Indena and Spectrum are not joint venturers, partners, principal and
agent, master and servant, employer or employee, and have no other relationship other than
independent contracting Parties. Indena and Spectrum shall have no power to bind or obligate each
other in any manner, other than as is expressly set forth in this Agreement.

28

 

     12.3 Entire Agreement; Modification. This Agreement sets forth the entire agreement and
understanding between the Parties as to the subject matter hereof. There shall be no amendments or
modifications to this Agreement, except by a written document which is signed by both Parties.

     12.4 Force Majeure. Neither Party shall be liable for any delay or failure of performance to
the extent such delay or failure is caused by circumstances beyond its reasonable control and that
by the exercise of due diligence it is unable to prevent, provided that the Party claiming excuse
uses its commercially reasonable efforts to overcome the same.

     12.5 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF CONFIDENTIALITY OR FOR
INFRINGEMENT OR MISAPPROPRIATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT,
INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO LOST PROFITS
(EXCEPT, HOWEVER, ANY LOST PROFITS OF SPECTRUM AS THE RESULT OF ANY BREACH BY INDENA OF ANY OF THE
REPRESENTATIONS IN SECTION 7.1 AND/OR THE COVENANTS IN ARTICLE 8), ARISING FROM OR RELATING TO ANY
BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.

     12.6 Assignment. Except for sublicensing rights as set forth in Section 2.2, this Agreement
nor any rights granted hereunder may be assigned or transferred by either Party without the prior
written consent of the non-assigning Party. Notwithstanding the foregoing, either Party may assign
this Agreement to (i) an Affiliate
or (ii) a Third Party in connection with the transfer or sale of all or substantially all of
the business of such Party to which this agreement relates whether by a merger, consolidation, sale
of stock, acquisition, sale of assets or otherwise. Subject to the limitations on assignment
herein, this Agreement shall be binding upon and inure to the benefit of any successors in interest
and permitted assigns of Indena and Spectrum. Any such successor or permitted assignee shall
expressly assume in writing the performance of all terms and conditions of this Agreement to be
performed by the assigning Party.

     12.7 Governing Law. This Agreement shall be construed and enforced in accordance with the
laws of the State of California, without regard to the conflicts of laws principles thereof.

     12.8 Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the
language contained in the particular article or section.

     12.9 Interpretation. The following provisions apply to this entire Agreement unless a
particular provision clearly specifies otherwise:

29

 

               (a) All references to monetary amounts are to the Euro, the official currency of the Eurozone.

               (b) The use of words in the singular or plural, or with a particular gender, shall not limit
the scope or exclude the application of any provision of this Agreement to such person or persons
or circumstances as the context otherwise permits.

               (c) The words “include” and “including” have the inclusive meaning “including without
limitation” and “including but not limited to.”

               (d) The word “day” shall mean a calendar day and the words “business day” shall mean a day
other than a Saturday, a Sunday, or any day that is a public holiday for employees of the U.S.
Federal government (as established by 5 U.S.C. 6103 or any statute that supersedes it).

               (e) Time periods within or following which any payment is to be made or act is to be done
shall be calculated by excluding the day on which the period commences and including the day
on which the period ends and by extending the period to the next business day following if the
last day of the period is not a business day in the jurisdiction of the Party to make such payment
or do such act.

               (f) Any reference to this Agreement or any other agreement, document or filing shall refer to
that item as amended from time to time.

               (g) Any reference to an Article, Section, Exhibit or Schedule shall be to the applicable
Article, Section, Exhibit or Schedule to this Agreement and not to or of any other document.

     12.10 Severability. Should any one or more of the provisions of this Agreement be held
invalid or unenforceable by a court of competent jurisdiction, it shall be considered severed from
this Agreement and shall not serve to invalidate the remaining provisions thereof. The Parties
shall make a good faith effort to replace any invalid or unenforceable provision with a valid and
enforceable one such that the objectives contemplated by them when entering this Agreement may be
realized.

     12.11 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver
as to a particular default or other matter shall not constitute a waiver of such Party’s rights to
the future enforcement of its rights under this Agreement, excepting only as to an express written
and signed waiver as to a particular matter for a particular period of time.

     12.12 Notices. Any notices required by this Agreement shall be in writing, shall specifically
refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or
by e-mail or telefax, confirmed by registered mail, or by telex or cable, charges prepaid, or by
overnight courier,

30

 

charges prepaid, and shall be delivered to the respective addresses set forth
below unless subsequently changed by written notice to the other Party:

	 	 	 
	For Indena:

	 	Indena SpA
	 

	 	Viale Ortles, 12
	 

	 	20139 Milano, Italy
	 

	 	Facsimile: (+39) 02 57496236
	 

	 	E-Mail: [***]
	 

	 	Attention: Gian Paolo Forni
	 
	 	 
	For Spectrum:

	 	Spectrum Pharmaceuticals, Inc.
	 

	 	157 Technology Drive
	 

	 	Irvine, CA 92618
	 

	 	Facsimile: (949) 788-6706
	 

	 	E-Mail: [***]
	 

	 	Attention: Rajesh C. Shrotriya, M.D.

Notice shall be deemed delivered upon the earlier of (i) when actually received, (ii) the date
notice is sent via e-mail, telefax, telex or cable, and confirmed by written receipt or (iii) the
day immediately following delivery to overnight courier, except that notices received on Sundays or
holidays will be deemed received the following business day.

     12.13 Compliance with Laws. Nothing contained in this Agreement shall require or permit
Indena or Spectrum to do any act inconsistent with the requirements of any Italian or United States
law, regulation or executive order as the same may be in effect from time to time.

     12.14 Counterparts. This Agreement may be executed simultaneously in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized
representatives as of the date first set forth above.

	 	 	 	 	 	 	 
	INDENA SPA	 	SPECTRUM PHARMACEUTICALS, INC.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Dario Bonacorsi
	 	By:
	 	/s/ Rajesh C. Shrotriya, M.D.
	 

	 	 
	 	 	 	 
	Name: Dario Bonacorsi	 	Name: Rajesh C. Shrotriya, M.D.
	Title: President and CEO	 	Title: Chairman, CEO and President

31

 

EXHIBIT A

IDN 5109

[***]

 

 

EXHIBIT B

LIST OF PATENTS

[***]

 

[Exhibit B, 11 pages, has been
omitted in its entirety and filed separately with the Securities and Exchange Commission.  Confidential treatment has been
requested with respect to the omitted pages.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]